113 related articles for article (PubMed ID: 27272204)
1. Unforeseen Severe Cardiotoxicity Associated With Daunorubicin Chemotherapy Even at a Dose Previously Thought to Be Safe: A Case Report.
Juan MCY; Jones RT; Thabolingam RC
Am J Ther; 2017; 24(4):e503-e504. PubMed ID: 27272204
[No Abstract] [Full Text] [Related]
2. Rabbit model for in vivo study of anthracycline-induced heart failure and for the evaluation of protective agents.
Simůnek T; Klimtová I; Kaplanová J; Mazurová Y; Adamcová M; Sterba M; Hrdina R; Gersl V
Eur J Heart Fail; 2004 Jun; 6(4):377-87. PubMed ID: 15182761
[TBL] [Abstract][Full Text] [Related]
3. Equivalence Ratio for Daunorubicin to Doxorubicin in Relation to Late Heart Failure in Survivors of Childhood Cancer.
Feijen EA; Leisenring WM; Stratton KL; Ness KK; van der Pal HJ; Caron HN; Armstrong GT; Green DM; Hudson MM; Oeffinger KC; Robison LL; Stovall M; Kremer LC; Chow EJ
J Clin Oncol; 2015 Nov; 33(32):3774-80. PubMed ID: 26304888
[TBL] [Abstract][Full Text] [Related]
4. Cardio-toxicity among patients with sarcoma: a cardio-oncology registry.
Shamai S; Rozenbaum Z; Merimsky O; Derakhshesh M; Moshkovits Y; Arnold J; Topilsky Y; Arbel Y; Laufer-Perl M
BMC Cancer; 2020 Jun; 20(1):609. PubMed ID: 32605637
[TBL] [Abstract][Full Text] [Related]
5. Cardiac safety profile of patients receiving high cumulative doses of pegylated-liposomal doxorubicin: use of left ventricular ejection fraction is of unproven value.
Skubitz KM; Blaes AH; Konety SH; Francis GS
Cancer Chemother Pharmacol; 2017 Oct; 80(4):787-798. PubMed ID: 28856562
[TBL] [Abstract][Full Text] [Related]
6. [A pilot study of high-dose zorubicin in advanced stages of soft tissue sarcoma in adults].
Jelić S; Tomasević Z; Kreacić M; Kovcin V; Radosavljević D; Vlajić M
Bull Cancer; 1996 Dec; 83(12):1002-7. PubMed ID: 9116363
[TBL] [Abstract][Full Text] [Related]
7. [Acute heart failure after a moderate dose of rubidomycin].
Baledent M; Messerschmitt J; Bens JL; Quiret JC; Faille N
Sem Hop; 1972 Feb; 48(7):507-10. PubMed ID: 4338408
[No Abstract] [Full Text] [Related]
8. Anthracycline induced cardiomyopathy: successful treatment with angiotensin converting enzyme inhibitors.
Hauser M; Wilson N
Eur J Pediatr; 2000 May; 159(5):389. PubMed ID: 10834529
[No Abstract] [Full Text] [Related]
9. Single-nucleotide polymorphisms in aldo-keto and carbonyl reductase genes are not associated with acute cardiotoxicity after daunorubicin chemotherapy.
Lubieniecka JM; Liu J; Heffner D; Graham J; Reid R; Hogge D; Grigliatti TA; Riggs WK
Cancer Epidemiol Biomarkers Prev; 2012 Nov; 21(11):2118-20. PubMed ID: 23001242
[TBL] [Abstract][Full Text] [Related]
10. Liposomal daunorubicin: new preparation. Kaposi's sarcoma: occasional remission.
Prescrire Int; 1998 Apr; 7(34):41-2. PubMed ID: 10183380
[TBL] [Abstract][Full Text] [Related]
11. [Cardioxan as a cardioprotector in antineoplastic chemotherapy].
Lichinitser MP; Vyshinskaia GV; Min'kov ED; Nakhalova TA; Odzharova AA; Garin AM
Klin Med (Mosk); 1996; 74(5):65-7. PubMed ID: 8999195
[No Abstract] [Full Text] [Related]
12. [Chemotherapy of uterine chorionepithelioma metastases to the lungs].
Savinova VF; Barinov VV
Akush Ginekol (Mosk); 1979 Dec; (12):43-5. PubMed ID: 575270
[No Abstract] [Full Text] [Related]
13. [Administration of liposomal preparation of DaunoXome for breast cancer in patients with poor prognosis].
Darskaia EI; Zubarovskaia LS; Afanas'ev BV
Vopr Onkol; 1999; 45(4):440-4. PubMed ID: 10532108
[TBL] [Abstract][Full Text] [Related]
14. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy.
Cardinale D; Colombo A; Bacchiani G; Tedeschi I; Meroni CA; Veglia F; Civelli M; Lamantia G; Colombo N; Curigliano G; Fiorentini C; Cipolla CM
Circulation; 2015 Jun; 131(22):1981-8. PubMed ID: 25948538
[TBL] [Abstract][Full Text] [Related]
15. Liposomal daunorubicin is not recommended in patients with less than advanced HIV-related Kaposi's sarcoma.
White RM
AIDS; 1997 Sep; 11(11):1412-3. PubMed ID: 9302461
[No Abstract] [Full Text] [Related]
16. DaunoXome shows promise as breast cancer treatment.
Oncology (Williston Park); 1996 Mar; 10(3):425. PubMed ID: 8820459
[No Abstract] [Full Text] [Related]
17. Phase II study of idarubicin in advanced endometrial carcinoma.
Hakes TB; Raymond V
Cancer Treat Rep; 1987 May; 71(5):535-6. PubMed ID: 3471330
[No Abstract] [Full Text] [Related]
18. Effectiveness of the combination therapy with lisinopril, ivabradine and multivitamin supplementation in anthracycline-induced severe cardiotoxicity.
de Gregorio C; Potenza G; Ferraro G
Int J Cardiol; 2014 Oct; 176(3):1374-6. PubMed ID: 25131909
[No Abstract] [Full Text] [Related]
19. [MODERN ASPECTS OF DIAGNOSIS AND TREATMENT OF HEART FAILURE, AS A MANIFESTATION OF ANTHRACYCLINE CARDIOTOXICITY (REVIEW)].
Saganelidze K; Kavtaradze N
Georgian Med News; 2018 May; (278):87-93. PubMed ID: 29905551
[TBL] [Abstract][Full Text] [Related]
20. Feasibility and pharmacokinetic study of infusional dexrazoxane and dose-intensive doxorubicin administered concurrently over 96 h for the treatment of advanced malignancies.
Chow WA; Synold TW; Tetef ML; Longmate J; Frankel P; Lawrence J; Al-Khadimi Z; Leong L; Lim D; Margolin K; Morgan RJ; Raschko J; Shibata S; Somlo G; Twardowski P; Yen Y; Doroshow JH
Cancer Chemother Pharmacol; 2004 Sep; 54(3):241-8. PubMed ID: 15173955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]